Oral Sildenafil in the management of primary pulmonary hypertension.
We report a case of primary pulmonary hypertension who benefited from oral Sildenafil therapy. Sildenafil, a selective phosphodiesterase type 5 inhibitor which acts as a pulmonary vasodilator, led to an improved clinical condition, exercise performance and haemodynamic parameters which were maintained at 6 months of follow up. Larger trials are warranted.
Malhotra
S
S
Department of Medicine, VMMC and Safdarjang Hospital, New Delhi-110 029.
Punia
V P S
VP
D000284:Administration, Oral; D000293:Adolescent; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D015150:Echocardiography, Doppler; D004562:Electrocardiography / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D006439:Hemodynamics / Q000502:physiology; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis* / Q000188:drug therapy*; D007194:India; D010879:Piperazines / Q000627:therapeutic use*; D049268:Positron-Emission Tomography / Q000379:methods; D011687:Purines; D012129:Respiratory Function Tests; D012720:Severity of Illness Index; D000068677:Sildenafil Citrate; D013450:Sulfones; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000008:administration & dosage*
D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate